Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-driven biotech momentum: Q2 revenue was $256.1M, up 32% YoY, EPS beat by a wide margin, LIFYORLI contributed $47.6M in its first quarter, and relacorilant NDA was resubmitted to the FDA. Shares are up about 33% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Liquidity ⢠Dilution Pressure CORT delivers exceptional margins, cash flow, and balance-sheet strength, but its elevated valuation and share dilution warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend intact ⢠Support under test ⢠Momentum weakening Support Level: $110.40â$110.50 Resistance Level: $115.70â$116.00 CORT's broader uptrend remains intact, but short-term momentum has weakened below its last-month average; watch $110.40â$110.50 support, with a break risking $108, while reclaiming $115.70â$116.00 would improve the setup.
Sentiment & News
Key News Insights: ⢠Lifyorli Momentum ⢠Institutional Buying ⢠Market Expansion Corcept's strong revenue growth, Lifyorli launch traction, and major institutional buying support a bullish outlook despite modest post-earnings weakness.
AI Summary
CORT has evolved into a profitable, cash-generative multi-franchise growth story as Lifyorli's strong oncology launch diversifies revenue, but its premium valuation leaves little room for slower adoption, core-franchise weakness, or relacorilant regulatory setbacksâmaking sustained execution the key buy/hold test.
Description
Corcept Therapeutics is a U.S.-based biopharmaceutical company that discovers, develops and commercializes drugs for severe metabolic, oncologic and neuropsychiatric conditions. It markets Korlym (mifepristone) for hyperglycemia secondary to endogenous Cushingâs syndrome in adults with type 2 diabetes or glucose intolerance who have not had successful surgery or are ineligible, and has clinical-stage programs including relacorilant for Cushingâs and combination studies with nab-paclitaxel in advanced ovarian tumors, alongside separate programs targeting prostate cancer, antipsychotic-induced weight gain and FKBP5-related diagnostics. Founded in 1998, the company is headquartered in Menlo Park, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jul 30 | Aug 6 | CORT | Corcept Therapeutics Incorporated | Catalyst-driven biotech momentum: Q2 revenue was $256.1M, up 32% YoY, EPS beat by a wide margin, LIFYORLI contributed $47.6M in its first quarter, and relacorilant NDA was resubmitted to the FDA. Shares are up about 33% over 21 trading days. | Closed | -8.8% |
| Jun 8 | Jun 15 | CORT | Corcept Therapeutics Incorporated | Event-driven biotech momentum: shares are up about 42% over 21 trading days, Corcept raised 2026 revenue guidance, plans to resubmit the relacorilant NDA in Cushing's syndrome, and recent clinical updates keep the catalyst calendar active. | Closed | +13.4% |